1999
DOI: 10.1073/pnas.96.24.14136
|View full text |Cite
|
Sign up to set email alerts
|

Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors

Abstract: Cannabinoids, including the endogenous ligand arachidonyl ethanolamide (anandamide), elicit not only neurobehavioral but also cardiovascular effects. Two cannabinoid receptors, CB1 and CB2, have been cloned, and studies with the selective CB1 receptor antagonist SR141716A have implicated peripherally located CB1 receptors in the hypotensive action of cannabinoids. In rat mesenteric arteries, anandamide-induced vasodilation is inhibited by SR141716A, but other potent CB1 receptor agonists, such as HU-210, do no… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

31
578
3
10

Year Published

2004
2004
2016
2016

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 569 publications
(623 citation statements)
references
References 40 publications
31
578
3
10
Order By: Relevance
“…This is in agreement with the findings of Chaytor et al (1999) for anandamide in similar isolated arterial preparations, but contrary to those of White & Hiley (1997). However, it is clear that some other CBs such as abnormal cannabidiol are clearly endothelium-dependent (Ja´rai et al, 1999). This might highlight some potential differences in the actions of various CB molecules.…”
Section: Discussionsupporting
confidence: 88%
See 4 more Smart Citations
“…This is in agreement with the findings of Chaytor et al (1999) for anandamide in similar isolated arterial preparations, but contrary to those of White & Hiley (1997). However, it is clear that some other CBs such as abnormal cannabidiol are clearly endothelium-dependent (Ja´rai et al, 1999). This might highlight some potential differences in the actions of various CB molecules.…”
Section: Discussionsupporting
confidence: 88%
“…However, in the nanomolar range, SR141716A did not affect responses to NADA, and, furthermore, the structurally similar CB 1 antagonist AM251 had no inhibitory effect on the potency of NADA at either 100 nM or 1 mM. This would appear to rule out the involvement of the CB 1 receptor in vasorelaxation to NADA in G3 vessels, but does not exclude the possibility of NADA acting at a novel CB receptor sensitive to SR141716A at 1 mM (Ja´rai et al, 1999;Offerta´ler et al, 2003). Interestingly, these findings are similar to work from Harris et al (2002), where vasorelaxation to anandamide was inhibited in the whole mesenteric arterial bed in the presence of SR141716A at 3 or 10 mM, but not 1 mM, and was not affected by another CB 1 receptor antagonist, LY320135, at 10 mM.…”
Section: Se O'sullivan Et Almentioning
confidence: 88%
See 3 more Smart Citations